|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
F2G Ltd Announces the Appointment of Dr Richard J. White as Chairman of the Board of Directors
2/24/2010 2:19:37 PM
Manchester, UK, 23 February 2010 - F2G Limited, the Manchester UK based antifungal drug
discovery and development company, today announced the appointment of Dr Richard J. White
as Chairman of the Company’s Board of Directors. Dr White has served as a non-executive
director of F2G Ltd since April 2006.
F2G also announced the appointment of a new non-executive director, Dr Sten Verland of
Sunstone Capital A/S.
"I congratulate Richard on his appointment as Chairman” said Shane M. Kelly, Chief Executive
of F2G Ltd. “Richard has a wealth of experience in infectious disease drug discovery gained
within Biotech and Pharma. He has been a tremendous asset to the Company during his time
on the Board and I look forward to working with him towards the further development of F2G Ltd.
The Board also welcomes Dr Sten Verland, whose proven expertise in building successful
businesses will be a valuable addition to the team.”
Dr Richard J. White commented ”This an exciting time for F2G as our lead program progresses
to clinical testing and I eagerly anticipate working closely with the other Board members".
About F2G Ltd:
Based in Manchester, UK, F2G Ltd is dedicated to the discovery and development of new and
clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk
patient populations. The antifungal market is currently estimated at over 6 billion dollars
annually and is growing steadily year on year. Market growth is expected to increase with the
emergence of new clinical indications in allergies and asthma.
The company has impressive internal capabilities, employing a core team of scientists with a
unique understanding of the antifungal arena, supported by an experienced management team.
F2G operates a flexible business model, building value through the development of a balanced
portfolio of antifungal assets across multiple validated TPPs.
For more information visit www.f2g.com
|
|
|
|
|
|
|
|
|
|
|